Monkeypox (MPX) cases continue to increase in the United States and across the globe. Concurrently, the availability of the best vaccine option— Jynneos—is constrained. As Bloomberg reported Wednesday, the Jynneos manufacturer isn’t certain it can meet demand. The U.S. has bought some time by switching to a dose-sparing strategy that involves giving the vaccine
It’s time for the ACAM2000 conversation
Monkeypox (MPX) cases continue to increase in the United States and across the globe. Concurrently, the availability of the best vaccine option— Jynneos—is constrained. As Bloomberg reported Wednesday, the Jynneos manufacturer isn’t certain it can meet demand. The U.S. has bought some time by switching to a dose-sparing strategy that involves giving the vaccine
Create your profile
Only paid subscribers can comment on this post
Check your email
For your security, we need to re-authenticate you.
Click the link we sent to , or click here to sign in.